Compare Mesoblast Limited (MESO) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Mesoblast Limited trades at $16.74 (market cap $2.21B), while Consumer Discretionary Select Sector SPDR Fund trades at $119.22. The key difference: Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | XLY | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | — |
52-Week High | $20.96 | $124.52 |
52-Week Low | $12.88 | $105.64 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
XLY trades at $118.02, down 1.38% today, with a bullish technical signal from moving averages but overbought RSI readings. Analyst consensus is unanimously positive, with a 100% buy rating. The ETF focuses on consumer discretionary stocks, benefiting from economic trends favoring the sector.
Outlook remains favorable due to strong analyst support and sector momentum, though overbought conditions and consumer spending sensitivity pose near-term risks. Long-term growth hinges on sustained economic strength and discretionary demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
